<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Endocrinol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Endocrinol</journal-id><journal-id journal-id-type="publisher-id">IJE</journal-id><journal-title-group><journal-title>International Journal of Endocrinology</journal-title></journal-title-group><issn pub-type="ppub">1687-8337</issn><issn pub-type="epub">1687-8345</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25254044</article-id><article-id pub-id-type="pmc">4164131</article-id><article-id pub-id-type="doi">10.1155/2014/653561</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Effects of a New Flavonoid and Myo-Inositol Supplement on Some Biomarkers of Cardiovascular Risk in Postmenopausal Women: A Randomized Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>D'Anna</surname><given-names>Rosario</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0872-8042</contrib-id><name><surname>Santamaria</surname><given-names>Angelo</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cannata</surname><given-names>Maria Letizia</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Interdonato</surname><given-names>Maria Lieta</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Giorgianni</surname><given-names>Grazia Maria</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Granese</surname><given-names>Roberta</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Corrado</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9300-7532</contrib-id><name><surname>Bitto</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Pediatric, Gynecological, Microbiological, and Biomedical Sciences, University of Messina, 98125 Messina, Italy</aff><aff id="I2"><sup>2</sup>Messina University Hospital, A.O.U. &#x0201c;G. Martino&#x0201d;, 98125 Messina, Italy</aff><aff id="I3"><sup>3</sup>Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy</aff><author-notes><corresp id="cor1">*Rosario D'Anna: <email>rdanna@unime.it</email></corresp><fn fn-type="other"><p>Academic Editor: Giuseppina T. Russo</p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>653561</elocation-id><history><date date-type="received"><day>1</day><month>7</month><year>2014</year></date><date date-type="rev-recd"><day>9</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>9</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Rosario D'Anna et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Background and Aim</italic>. Cardiovascular risk is increased in women with menopause and metabolic syndrome. Aim of this study was to test the effect of a new supplement formula, combining cocoa polyphenols, myo-inositol, and soy isoflavones, on some biomarkers of cardiovascular risk in postmenopausal women with metabolic syndrome.<italic> Methods and Results</italic>. A total of 60 women were enrolled and randomly assigned (<italic>n</italic> = 30 per group) to receive the supplement (NRT: 30&#x02009;mg of cocoa polyphenols, 80&#x02009;mg of soy isoflavones, and 2&#x02009;gr of myo-inositol), or placebo for 6 months. The study protocol included three visits (baseline, 6, and 12 months) for the evaluation of glucose, triglycerides, and HDL-cholesterol (HDL-C), adiponectin, visfatin, resistin, and bone-specific alkaline phosphatase (bone-ALP). At 6 months, a significant difference between NRT and placebo was found for glucose (96 &#x000b1; 7 versus 108 &#x000b1; 10&#x02009;mg/dL), triglycerides (145 &#x000b1; 14 versus 165 &#x000b1; 18&#x02009;mg/dL), visfatin (2.8 &#x000b1; 0.8 versus 3.7 &#x000b1; 1.1&#x02009;ng/mL), resistin (27 &#x000b1; 7 versus 32 &#x000b1; 8&#x02009;<italic>&#x000b5;</italic>g/L), and b-ALP (19 &#x000b1; 7 versus 15 &#x000b1; 5&#x02009;<italic>&#x000b5;</italic>g/mL). No difference in HDL-C concentrations nor in adiponectin levels between groups was reported at 6 months.<italic> Conclusions.</italic> The supplement used in this study improves most of the biomarkers linked to metabolic syndrome. This Trial is registered with <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=NCT01400724&#x00026;Search=Search">NCT01400724</ext-link>.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Cardiovascular disease (CVD) events remain the leading cause of mortality and are a major cause of morbidity and disability in both genders worldwide [<xref rid="B1" ref-type="bibr">1</xref>]. CVDs cover a collection of various heart and vascular diseases, among these hypertension, coronary heart, and cerebrovascular diseases represent major public health problems. It is well known that in postmenopausal CVD risk is increased, since the protective effects exerted by estrogens are missing. It is a matter of fact that following menopause, negative changes in blood pressure, glucose level, and lipid profile are frequent, and characterize the so called &#x0201c;metabolic syndrome&#x0201d;, responsible for increased CVD risk [<xref rid="B2" ref-type="bibr">2</xref>]. Furthermore, the majority of postmenopausal women experience an undesirable weight gain. CVDs have multiple causes; however, most of the events originate from the complications of atherosclerosis, a pathophysiological process that can be prevented by dietary habit [<xref rid="B3" ref-type="bibr">3</xref>]. Evidence from epidemiological studies indicates a positive association between reduction in the incidence of CVD and consumption of plant-based foods such as fruit and vegetables [<xref rid="B4" ref-type="bibr">4</xref>]. In addition, the relationship between the amount of polyphenol-rich food consumption (fruit and fruit juices, tea, wine, and cocoa) and chronic diseases, supports a protective effect of these compounds upon CVD [<xref rid="B5" ref-type="bibr">5</xref>]. The meta-analysis by Desch and colleagues [<xref rid="B6" ref-type="bibr">6</xref>] has confirmed the blood pressure-lowering capacity of flavonol-rich cocoa products, in a large set of trials. It has been estimated that a 3&#x02009;mmHg reduction in systolic blood pressure (SBP) would reduce the relative risk of stroke mortality by 8%, coronary artery disease (CAD) mortality by 5%, and all-cause of mortality by 4% [<xref rid="B7" ref-type="bibr">7</xref>]. Other effects of cocoa-derived products include the improved platelet function [<xref rid="B8" ref-type="bibr">8</xref>] and the reduction of LDL-cholesterol [<xref rid="B4" ref-type="bibr">4</xref>], the major atherogenic lipoprotein.</p><p>Besides cocoa flavanols, many other dietary substances have a proven efficacy in reducing CVD risk markers; in previous studies we already shown the protective effects of two naturally occurring molecules, the isoflavone genistein [<xref rid="B9" ref-type="bibr">9</xref>] and myo-inositol [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>], produced by the human body from glucose. Inositol is a polyol which may be considered a second messenger of insulin [<xref rid="B12" ref-type="bibr">12</xref>], and myo-inositol is one of its nine isomers, capable of reducing insulin resistance, blood pressure, and improving lipid profile in a small cohort of postmenopausal women affected by metabolic syndrome [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. The soy-derived isoflavone genistein acting as a natural selective estrogen receptor modulator (SERM) has a proven efficacy on markers of CVD risk [<xref rid="B9" ref-type="bibr">9</xref>] and in reducing bone loss in postmenopausal women [<xref rid="B13" ref-type="bibr">13</xref>]. Very recently, genistein has shown to reduce insulin resistance, blood pressure, and homocysteine and it improved lipid profile in a cohort of women with metabolic syndrome [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>In light of these previous experiences and observations, the aim of this study was to test a new supplement formula, combining cocoa polyphenols, myo-inositol, and soy isoflavones, in postmenopausal women with metabolic syndrome. The rationale for this combination therapy is to offer a natural replacement therapy (NRT) that might improve the metabolic conditions in postmenopausal women. In particular, cocoa polyphenols are antioxidants; inositol is an insulin sensitizing agent and soy isoflavones have a positive effect also on bone metabolism.</p></sec><sec id="sec2"><title>2. Subjects and Methods</title><sec id="sec2.1"><title>2.1. Enrollment and Randomization to Treatments</title><p>A 12-month, randomized, open-label study was performed. The study protocol was consistent with the principles of the Declaration of Helsinki and has been approved by the Ethics Committee of the University of Messina, Italy. All participants gave written informed consent. Women (<italic>n</italic> = 60) were recruited at the Menopause Outpatients of the University of Messina. Following the criteria for inclusion, women had to be 50 to 60 years old, postmenopausal for at least 12 months at baseline, and diagnosed with metabolic syndrome. Based on the NCEP ATP III [<xref rid="B15" ref-type="bibr">15</xref>], the diagnosis of metabolic syndrome in women requires three or more of the five following criteria: (1) waist circumference &#x02265; 88&#x02009;cm; (2) triglycerides &#x02265; 150&#x02009;mg/dL or on drug treatment for elevated triglycerides; (3) HDL-C &#x0003c; 50&#x02009;mg/dL or on drug treatment for reduced HDL-C; (4) fasting glucose &#x02265; 100&#x02009;mg/dL or on drug treatment for hyperglycemia; (5) blood pressure &#x02265; 130/85&#x02009;mmHg or on antihypertensive drug. At enrollment a complete family history was obtained and physical examination and routine laboratory evaluation were performed. Almost all the women were hypertensive (55/60) and in treatment with antihypertensive agents.</p><p>Exclusion criteria were clinical or laboratory evidence of confounding systemic diseases (e.g., chronic renal or hepatic failure and chronic inflammatory diseases); breast affections or familiar history of breast disease; CVD defined as documented myocardial infarction, ischemic heart disease, coronary heart bypass, coronary angioplasty, cerebral thromboembolism, peripheral amputations, and coagulopathy; use of oral or transdermal estrogen, progestin, androgens, selective estrogen receptor modulators, or other steroids; treatment in the preceding six months with polyunsaturated n-3 fatty acids supplements and nonsteroidal anti-inflammatory drugs (NSAIDs); smoking habit of more than 2 cigarettes daily. Furthermore, subjects were advised to report on occasional use of NSAIDs to the study investigators. Additional exclusion criteria included history of alcohol or drug abuse, being enrolled in another clinical study, proven hypersensitivity to the study drugs, and concomitant major diseases. A computer generated randomization with sequence random permuted blocks was used to minimize differences between groups, due to the limited number of women. Subjects were assigned to the intervention group (NRT: <italic>n</italic> = 30) or to the placebo group (<italic>n</italic> = 30).</p><p>All participants were counseled on a Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% from saturated fatty acids, 55% to 60% from carbohydrates, and 15% from protein, with a cholesterol intake less than 300&#x02009;mg/d and fiber intake of 35&#x02009;g/d or greater. We used this diet to avoid interference with the lipid profile. Diet adherence was evaluated in all participants during each follow-up visit. Soy products or other dietary supplements were prohibited whereas legumes' intake was suggested to be kept constant overtime. At least 150 minutes per week of moderately intense physical activity (walking or cycling) was recommended.</p><p>The treatment (herein after NRT) was given for 6 months and it was composed of 30&#x02009;mg of cocoa polyphenols, 80&#x02009;mg of soy isoflavones, and 2 grams of myo-inositol. Both NRT and placebo were in powder. In the following 6-month period only diet was recommended to both groups. Women were followed monthly with telephone calls to reinforce the adherence to the intervention.</p><p>The study protocol included three visits (baseline, 6, and 12 months) for evaluation of serum glucose, triglycerides, and HDL-C together with some adipokines: adiponectin, visfatin, and resistin; and a marker of bone turnover: bone-ALP.</p></sec><sec id="sec2.2"><title>2.2. Determination of the Study Variables</title><p>Primary outcome was the improvement (as a 20% change from baseline) of at least one of the parameters that characterize metabolic syndrome: blood pressure, waist circumference, HDL-cholesterol, triglycerides, and fasting glucose. Secondary outcome was the improvement of the studied markers as adiponectin, resistin, visfatin, and bone-ALP.</p><p>Fasting glucose was measured using routine colorimetric method (normal range 65&#x02013;110&#x02009;mg/dL). HDL-C and triglycerides were measured by using a routine enzymatic method (SGM Italia, Italy).</p><p>Adiponectin, resistin (all from DRG International Inc., Marburg, Germany), bone-specific alkaline phosphatase (IDS, ltd, Fountain Hills, AZ), and visfatin (Ucsn Life Science, Inc., Houston, TX) were measured using enzyme-linked immunosorbent assay kits from serum samples. Adiponectin limit of detection was 0.2&#x02009;<italic>&#x003bc;</italic>g/mL with an intra-assay CV of 7.5% and an interassay CV of 6.5%. Resistin limit of detection was 0.012&#x02009;ng/mL with an intra-assay CV of 5.2% and an interassay CV of 7%. Visfatin limit of detection was 6.3&#x02009;pg/mL with an intra-assay CV of 9% and an interassay CV of 10%. Bone-ALP limit of detection was 0.7&#x02009;<italic>&#x003bc;</italic>g/L with an intra-assay CV of 4.5% and an interassay CV of 5.8%.</p></sec><sec id="sec2.3"><title>2.3. Adverse Events</title><p>Participants were also followed and monitored by their general practitioners (who served as external monitors), who received a detailed synopsis of the trial and were unaware of the treatment arm. At clinical visit every 6 months, women were asked about symptoms. Standard clinical evaluations and routinary laboratory analyses were done every 6 months. All unfavorable and unintended clinical effects were considered adverse events and were evaluated for severity, duration, seriousness, and relation to the study drug and outcome.</p></sec><sec id="sec2.4"><title>2.4. Statistical Analysis</title><p>The analysis-of-variance (ANOVA) for repeated measures was performed to analyze treatment effects on groups and time and the unpaired <italic>t</italic>-test was used to compare mean differences in continuous variables intra- and intergroups. A <italic>P</italic> value of 0.05 or less was considered statistically significant. A post hoc power calculation analysis demonstrated over 95% power when considering as primary endpoint either glycemia or triglycerides, with an alpha error of 0.05. Statistical analysis was performed by using Statistical Package for Social Science (SPSS Statistics 17.0 Chicago, IL) software.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>At the beginning of the study, the 2 groups were comparable for age, BMI, months from menopause, waist circumferences, and blood pressure (<xref ref-type="table" rid="tab1">Table 1</xref>); and for clinical characteristics: serum glucose, HDL-cholesterol, and triglycerides (<xref ref-type="table" rid="tab2">Table 2</xref>).</p><p>At the end of the 6 months treatment period, only 26 in the NRT group and 24 in the placebo group remained in the study (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In the following six-month period other dropouts occurred, thus only 22 in the treated group and 21 in the placebo group completed the study. Reasons for withdrawal were abdominal pain (3 cases) and throat dryness (2 cases) and other reasons were not reported.</p><p>At 6 months, a significant difference between NRT and placebo was found for glucose, triglycerides, b-ALP, visfatin, and resistin as reported in <xref ref-type="table" rid="tab2">Table 2</xref> and Figures <xref ref-type="fig" rid="fig2">2</xref> and <xref ref-type="fig" rid="fig3">3</xref>. No difference in HDL-C concentrations nor in adiponectin levels between groups was reported at 6 months (<xref ref-type="table" rid="tab2">Table 2</xref> and Figures <xref ref-type="fig" rid="fig2">2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). At 12 months, after 6 months from the end of the treatment period, in addition to glucose, triglycerides, b-ALP, visfatin, and resistin, also adiponectin levels were significantly changed in NRT group, compared to placebo (<xref ref-type="table" rid="tab2">Table 2</xref> and Figures <xref ref-type="fig" rid="fig2">2</xref> and <xref ref-type="fig" rid="fig3">3</xref>).</p><p>The intra-group analysis revealed that only HDL-C and adiponectin were not affected by NRT treatment at the end of the 6 months, while all the other studied variables were significantly changed from basal values (<xref ref-type="table" rid="tab2">Table 2</xref> and Figures <xref ref-type="fig" rid="fig2">2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). In the placebo group after 6 months a significant difference from basal values was observed for triglycerides and adiponectin, probably due to diet, despite no changes in BMI were noted in the enrolled subjects (<xref ref-type="table" rid="tab2">Table 2</xref> and Figures <xref ref-type="fig" rid="fig2">2</xref> and <xref ref-type="fig" rid="fig3">3</xref>).</p></sec><sec id="sec4"><title>4. Discussion</title><p>The results of this study demonstrate a protective effect on cardiovascular markers following 6 months administration of a combination of myo-inositol, soy isoflavones, and cocoa polyphenols, in postmenopausal women with metabolic syndrome.</p><p>A limit of this study is the number of women enrolled, which reduced the statistical significance of the outcomes; in spite of all that, some interesting results have been obtained. One of these was the persistence, in the six months follow-up period, of the positive results achieved during the six-month treatment period; this data concerns all the markers studied. No differences were highlighted in BMI and waist circumference between and within groups, but this may be due to the short treatment period and somewhat to the low adherence to diet. In the treated group, serum glucose and triglycerides values significantly decreased after six months, maintaining in the subsequent 6 months a significant difference from basal levels. These results are in accordance with other studies, in which each component of the supplement of this trial was used [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. No difference in HDL-C was shown either between groups or from 6-month to basal values; this data is confirmed by some studies in which only cocoa polyphenols were used [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B17" ref-type="bibr">17</xref>], but not by others [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B16" ref-type="bibr">16</xref>], in which a significant difference compared to control group was shown, when each single component of the supplement studied was used. Blood pressure didn't significantly change through the study period, although significant differences were highlighted in other studies in which either myo-inositol or cocoa polyphenols were used [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>]; probably the limited number of women studied has negatively influenced this outcome. More interesting were the data about biomarkers which usually depend on insulin resistance. In particular, serum adiponectin levels were significantly increased, after 12 months, in the treated group compared to the control group and also increased at 12 months from basal values in the same group. This result is in accordance with a recent study of our group where genistein aglycone was used [<xref rid="B14" ref-type="bibr">14</xref>]. Adiponectin is an adipocyte-specific, secreted protein that sensitizes the liver and muscle to the action of insulin [<xref rid="B18" ref-type="bibr">18</xref>]. It is the only adipocyte-derived hormone to be downregulated in the insulin-resistant state, so the levels of adiponectin strongly correlate with basal insulin levels and insulin sensitivity [<xref rid="B19" ref-type="bibr">19</xref>]. This explains why low concentrations of adiponectin are associated with increased prevalence of metabolic syndrome, especially in postmenopausal women [<xref rid="B20" ref-type="bibr">20</xref>]. If an improvement of insulin resistance is expeceted using isoflavones, because they act through estrogen receptors; or myo-inositol, because of its insulin-like effect [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]; an insulin sensitizing effect is not yet clear for cocoa polyphenols. According to Grassi and coworkers [<xref rid="B21" ref-type="bibr">21</xref>], a possible explanation might be found in the positive effect that cocoa extracts have on endothelium-dependent relaxation; in fact, since insulin sensitivity may be in part considered dependent on NO availability, cocoa polyphenols may improve NO production and insulin sensitivity as a consequence [<xref rid="B22" ref-type="bibr">22</xref>]. For resistin and visfatin a significant difference occurred only in the treated group, in which both markers were significantly reduced after 6 months of supplement assumption, reaching a plateau until the 12th month. Resistin, is a peptide hormone produced by adipocytes that is more highly expressed in omental and abdominal subcutaneous white fat [<xref rid="B23" ref-type="bibr">23</xref>]. In postmenopausal, and in obese women, resistin levels nearly double, representing the hormone that links obesity to diabetes [<xref rid="B24" ref-type="bibr">24</xref>]; in addition, a close association of resistin to metabolic syndrome has been recently established [<xref rid="B25" ref-type="bibr">25</xref>]. Visfatin role is controversial, but recent evidences have shown increased serum levels in overweight/obese, type-2 diabetics, metabolic syndrome, and CVD patients [<xref rid="B26" ref-type="bibr">26</xref>]. Kim and coworkers [<xref rid="B27" ref-type="bibr">27</xref>] have suggested that visfatin may act as the underlying pathophysiological trigger for metabolic syndrome in postmenopausal women and as a marker of abdominal fat deposition and tissue inflammation. The here reported significant reduction in visfatin values, is in agreement with our recent findings in postmenopausal women with metabolic syndrome taking the isoflavone genistein for 12 months [<xref rid="B14" ref-type="bibr">14</xref>]. Among the biomarkers evaluated, bone-ALP was also included. This molecule is synthesized by the osteoblasts and it is considered a specific marker of bone formation [<xref rid="B28" ref-type="bibr">28</xref>]. In this study, the group receiving the combination formula showed increased levels of bone-ALP over time, with significant differences compared to the placebo group after 12 months and a significant difference with respect to basal values. This result is in accordance with a previous study [<xref rid="B29" ref-type="bibr">29</xref>], showing that 54&#x02009;mg of genistein improved bone turnover, prevented osteoporosis, and increased bone mass density in postmenopausal osteopenic women. Thus, we may hypothesize that probably isoflavones have determined an improvement in bone turnover; however, an experimental study [<xref rid="B30" ref-type="bibr">30</xref>] has shown that also myo-inositol is essential for osteogenesis and bone formation.</p><p>In conclusion, the supplement used in this study has shown to improve most of the biomarkers linked to metabolic syndrome, suggesting a possible reduction of CVD risk. Furthermore, this study has shown that the positive effects of the supplement may last in the subsequent six months, together with an increase in bone formation. Further studies are warranted to reproduce the present data in a larger cohort of postmenopausal women with metabolic syndrome.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work has been supported by departmental funding.</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><collab>World Health Organization</collab><source><italic>The Global Burden of Disease: 2004 Update</italic></source><year>2008</year><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isomaa</surname><given-names>B</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cardiovascular morbidity and mortality associated with the metabolic syndrome</article-title><source><italic>Diabetes Care</italic></source><year>2001</year><volume>24</volume><issue>4</issue><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="other">2-s2.0-0034837376</pub-id><pub-id pub-id-type="pmid">11315831</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Toole</surname><given-names>TE</given-names></name><name><surname>Conklin</surname><given-names>DJ</given-names></name><name><surname>Bhatnagar</surname><given-names>A</given-names></name></person-group><article-title>Environmental risk factors for heart disease</article-title><source><italic>Reviews on Environmental Health</italic></source><year>2008</year><volume>23</volume><issue>3</issue><fpage>167</fpage><lpage>202</lpage><pub-id pub-id-type="other">2-s2.0-56849114813</pub-id><pub-id pub-id-type="pmid">19119685</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dauchet</surname><given-names>L</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Dallongeville</surname><given-names>J</given-names></name></person-group><article-title>Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies</article-title><source><italic>Neurology</italic></source><year>2005</year><volume>65</volume><issue>8</issue><fpage>1193</fpage><lpage>1197</lpage><pub-id pub-id-type="other">2-s2.0-27144551652</pub-id><pub-id pub-id-type="pmid">16247045</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials</article-title><source><italic>The American Journal of Clinical Nutrition</italic></source><year>2010</year><volume>92</volume><issue>1</issue><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="other">2-s2.0-77954582753</pub-id><pub-id pub-id-type="pmid">20504978</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desch</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>J</given-names></name><name><surname>Kobler</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of cocoa products on blood pressure: systematic review and meta-analysis</article-title><source><italic>The American Journal of Hypertension</italic></source><year>2010</year><volume>23</volume><issue>1</issue><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="other">2-s2.0-72449139017</pub-id><pub-id pub-id-type="pmid">19910929</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program</article-title><source><italic>Journal of the American Medical Association</italic></source><year>2002</year><volume>288</volume><issue>15</issue><fpage>1882</fpage><lpage>1888</lpage><pub-id pub-id-type="other">2-s2.0-0037120907</pub-id><pub-id pub-id-type="pmid">12377087</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>F</given-names></name><name><surname>Spieker</surname><given-names>LE</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><etal/></person-group><article-title>Dark chocolate improves endothelial and platelet function</article-title><source><italic>Heart</italic></source><year>2006</year><volume>92</volume><issue>1</issue><fpage>119</fpage><lpage>120</lpage><pub-id pub-id-type="other">2-s2.0-29644444206</pub-id><pub-id pub-id-type="pmid">16365364</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atteritano</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>H</given-names></name><name><surname>Minutoli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2007</year><volume>92</volume><issue>8</issue><fpage>3068</fpage><lpage>3075</lpage><pub-id pub-id-type="other">2-s2.0-34547742675</pub-id><pub-id pub-id-type="pmid">17682090</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>D</given-names></name><name><surname>Corrado</surname><given-names>F</given-names></name><name><surname>Santamaria</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study</article-title><source><italic>Menopause</italic></source><year>2011</year><volume>18</volume><issue>1</issue><fpage>102</fpage><lpage>104</lpage><pub-id pub-id-type="other">2-s2.0-78651404451</pub-id><pub-id pub-id-type="pmid">20811299</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santamaria</surname><given-names>A</given-names></name><name><surname>Giordano</surname><given-names>D</given-names></name><name><surname>Corrado</surname><given-names>F</given-names></name><etal/></person-group><article-title>One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome</article-title><source><italic>Climacteric</italic></source><year>2012</year><volume>15</volume><issue>5</issue><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="other">2-s2.0-84866370256</pub-id><pub-id pub-id-type="pmid">22192068</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltiel</surname><given-names>AR</given-names></name></person-group><article-title>Second messengers of insulin action</article-title><source><italic>Diabetes Care</italic></source><year>1990</year><volume>13</volume><issue>3</issue><fpage>244</fpage><lpage>256</lpage><pub-id pub-id-type="other">2-s2.0-0025304396</pub-id><pub-id pub-id-type="pmid">2137771</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marini</surname><given-names>H</given-names></name><name><surname>Minutoli</surname><given-names>L</given-names></name><name><surname>Polito</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2007</year><volume>146</volume><issue>12</issue><fpage>839</fpage><lpage>847</lpage><pub-id pub-id-type="other">2-s2.0-34347383831</pub-id><pub-id pub-id-type="pmid">17577003</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squadrito</surname><given-names>F</given-names></name><name><surname>Marini</surname><given-names>H</given-names></name><name><surname>Bitto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genistein in the metabolic syndrome: results of a randomized clinical trial</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2013</year><volume>98</volume><issue>8</issue><fpage>3366</fpage><lpage>3374</lpage><pub-id pub-id-type="other">2-s2.0-84881486464</pub-id><pub-id pub-id-type="pmid">23824420</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Daniels</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement</article-title><source><italic>Circulation</italic></source><year>2005</year><volume>112</volume><issue>17</issue><fpage>2735</fpage><lpage>2752</lpage><pub-id pub-id-type="other">2-s2.0-27444443876</pub-id><pub-id pub-id-type="pmid">16157765</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarri&#x000e1;</surname><given-names>B</given-names></name><name><surname>Mart&#x000ed;nez-L&#x000f3;pez</surname><given-names>S</given-names></name><name><surname>Sierra-Cinos</surname><given-names>JL</given-names></name><name><surname>Garc&#x000ed;a-Diz</surname><given-names>L</given-names></name><name><surname>Mateos</surname><given-names>R</given-names></name><name><surname>Bravo</surname><given-names>L</given-names></name></person-group><article-title>Regular consumption of a cocoa product improves the cardiometabolic profile in healthy and moderately hypercholesterolaemic adults</article-title><source><italic>The British Journal of Nutrition</italic></source><year>2014</year><volume>111</volume><issue>1</issue><fpage>122</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">23823716</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogueira</surname><given-names>LDP</given-names></name><name><surname>Knibel</surname><given-names>MP</given-names></name><name><surname>Torres</surname><given-names>MRSG</given-names></name><name><surname>Nogueira Neto</surname><given-names>JF</given-names></name><name><surname>Sanjuliani</surname><given-names>AF</given-names></name></person-group><article-title>Consumption of high-polyphenol dark chocolate improves endothelial function in individuals with stage 1 hypertension and excess body weight</article-title><source><italic>International Journal of Hypertension</italic></source><year>2012</year><volume>2012</volume><fpage>9 pages</fpage><pub-id pub-id-type="publisher-id">147321</pub-id><pub-id pub-id-type="other">2-s2.0-84870216773</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kamon</surname><given-names>J</given-names></name><name><surname>Waki</surname><given-names>H</given-names></name><etal/></person-group><article-title>The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity</article-title><source><italic>Nature Medicine</italic></source><year>2001</year><volume>7</volume><issue>8</issue><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="other">2-s2.0-17944365228</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catalano</surname><given-names>PM</given-names></name><name><surname>Hoegh</surname><given-names>M</given-names></name><name><surname>Minium</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism</article-title><source><italic>Diabetologia</italic></source><year>2006</year><volume>49</volume><issue>7</issue><fpage>1677</fpage><lpage>1685</lpage><pub-id pub-id-type="other">2-s2.0-33744945757</pub-id><pub-id pub-id-type="pmid">16752186</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henneman</surname><given-names>P</given-names></name><name><surname>Janssens</surname><given-names>ACJW</given-names></name><name><surname>Zillikens</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Menopause impacts the relation of plasma adiponectin levels with the metabolic syndrome</article-title><source><italic>Journal of Internal Medicine</italic></source><year>2010</year><volume>267</volume><issue>4</issue><fpage>402</fpage><lpage>409</lpage><pub-id pub-id-type="other">2-s2.0-77949354118</pub-id><pub-id pub-id-type="pmid">19912464</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grassi</surname><given-names>D</given-names></name><name><surname>Lippi</surname><given-names>C</given-names></name><name><surname>Necozione</surname><given-names>S</given-names></name><name><surname>Desideri</surname><given-names>G</given-names></name><name><surname>Ferri</surname><given-names>C</given-names></name></person-group><article-title>Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons</article-title><source><italic>The American Journal of Clinical Nutrition</italic></source><year>2005</year><volume>81</volume><issue>3</issue><fpage>611</fpage><lpage>614</lpage><pub-id pub-id-type="other">2-s2.0-15744388677</pub-id><pub-id pub-id-type="pmid">15755830</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karim</surname><given-names>M</given-names></name><name><surname>McCormick</surname><given-names>K</given-names></name><name><surname>Tissa Kappagoda</surname><given-names>C</given-names></name></person-group><article-title>Effects of cocoa extracts on endothelium-dependent relaxation</article-title><source><italic>Journal of Nutrition</italic></source><year>2000</year><volume>130</volume><issue>8S, supplement</issue><fpage>2105S</fpage><lpage>2108S</lpage><pub-id pub-id-type="other">2-s2.0-0033862093</pub-id><pub-id pub-id-type="pmid">10917930</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTernan</surname><given-names>CL</given-names></name><name><surname>McTernan</surname><given-names>PG</given-names></name><name><surname>Harte</surname><given-names>AL</given-names></name><name><surname>Levick</surname><given-names>PL</given-names></name><name><surname>Barnett</surname><given-names>AH</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Resistin, central obesity, and type 2 diabetes</article-title><source><italic>The Lancet</italic></source><year>2002</year><volume>359</volume><issue>9300</issue><fpage>46</fpage><lpage>47</lpage><pub-id pub-id-type="other">2-s2.0-0037022005</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steppan</surname><given-names>CM</given-names></name><name><surname>Bailey</surname><given-names>ST</given-names></name><name><surname>Bhat</surname><given-names>S</given-names></name><etal/></person-group><article-title>The hormone resistin links obesity to diabetes</article-title><source><italic>Nature</italic></source><year>2001</year><volume>409</volume><issue>6818</issue><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="other">2-s2.0-0035905758</pub-id><pub-id pub-id-type="pmid">11201732</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malo</surname><given-names>E</given-names></name><name><surname>Ukkola</surname><given-names>O</given-names></name><name><surname>Jokela</surname><given-names>M</given-names></name><etal/></person-group><article-title>Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish health 2000 survey</article-title><source><italic>Metabolic Syndrome and Related Disorders</italic></source><year>2011</year><volume>9</volume><issue>3</issue><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="other">2-s2.0-79957667032</pub-id><pub-id pub-id-type="pmid">21332410</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name></person-group><article-title>Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review</article-title><source><italic>Diabetes/Metabolism Research and Reviews</italic></source><year>2011</year><volume>27</volume><issue>6</issue><fpage>515</fpage><lpage>527</lpage><pub-id pub-id-type="other">2-s2.0-80052583612</pub-id><pub-id pub-id-type="pmid">21484978</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Im</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name></person-group><article-title>The relationship between visfatin and metabolic syndrome in postmenopausal women</article-title><source><italic>Maturitas</italic></source><year>2010</year><volume>67</volume><issue>1</issue><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="other">2-s2.0-77955918010</pub-id><pub-id pub-id-type="pmid">20537826</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>PD</given-names></name><name><surname>Knowlton</surname><given-names>W</given-names></name></person-group><article-title>Rapid bone loss is associated with increased levels of biochemical markers</article-title><source><italic>Journal of Bone and Mineral Research</italic></source><year>1998</year><volume>13</volume><issue>2</issue><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="other">2-s2.0-0031937226</pub-id><pub-id pub-id-type="pmid">9495524</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marini</surname><given-names>H</given-names></name><name><surname>Bitto</surname><given-names>A</given-names></name><name><surname>Altavilla</surname><given-names>D</given-names></name><etal/></person-group><article-title>Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2008</year><volume>93</volume><issue>12</issue><fpage>4787</fpage><lpage>4796</lpage><pub-id pub-id-type="other">2-s2.0-57349142997</pub-id><pub-id pub-id-type="pmid">18796517</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Chung</surname><given-names>SK</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Lau</surname><given-names>KS</given-names></name><name><surname>Chan</surname><given-names>AWH</given-names></name><name><surname>Kung</surname><given-names>AWC</given-names></name></person-group><article-title>Sodium/myo-inositol cotransporter 1 and myo-inositol are essential for osteogenesis and bone formation</article-title><source><italic>Journal of Bone and Mineral Research</italic></source><year>2011</year><volume>26</volume><issue>3</issue><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="other">2-s2.0-79951842355</pub-id><pub-id pub-id-type="pmid">20818642</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study flow chart.</p></caption><graphic xlink:href="IJE2014-653561.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Glucose, triglycerides and HDL-cholesterol blood levels through the study. *<italic>P</italic> &#x0003c; 0.05 versus basal.</p></caption><graphic xlink:href="IJE2014-653561.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Adiponectin, visfatin, resistin, and bone-ALP blood levels through the study. *<italic>P</italic> &#x0003c; 0.05 versus basal; <sup>&#x000a7;</sup>
<italic>P</italic> &#x0003c; 0.05 versus placebo.</p></caption><graphic xlink:href="IJE2014-653561.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study groups (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">NRT <italic>n</italic> = 30 &#x02009;<break/>(basal)</th><th align="center" rowspan="1" colspan="1">Placebo <italic>n</italic> = 30&#x02009; <break/>(basal)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="center" rowspan="1" colspan="1">NRT <italic>n</italic> = 26 &#x02009;<break/>(6 months)</th><th align="center" rowspan="1" colspan="1">Placebo <italic>n</italic> = 24&#x02009;<break/> (6 months)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">56.3 &#x000b1; 3.8</td><td align="center" rowspan="1" colspan="1">55.5 &#x000b1; 4.8</td><td align="center" rowspan="1" colspan="1">0.3</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Menopause (months)</td><td align="center" rowspan="1" colspan="1">95.1 &#x000b1; 61.6</td><td align="center" rowspan="1" colspan="1">75.6 &#x000b1; 57</td><td align="center" rowspan="1" colspan="1">0.2</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (Kg/m&#x000b2;)</td><td align="center" rowspan="1" colspan="1">31.9 &#x000b1; 3.8</td><td align="center" rowspan="1" colspan="1">33.6 &#x000b1; 3.9</td><td align="center" rowspan="1" colspan="1">0.1</td><td align="center" rowspan="1" colspan="1">30.7 &#x000b1; 3.9</td><td align="center" rowspan="1" colspan="1">33.3 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">123.6 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">132.6 &#x000b1; 20</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">124 &#x000b1; 9.1</td><td align="center" rowspan="1" colspan="1">121.6 &#x000b1; 9.8</td><td align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">80 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">81.5 &#x000b1; 11.9</td><td align="center" rowspan="1" colspan="1">0.3</td><td align="center" rowspan="1" colspan="1">73.6 &#x000b1; 11.2</td><td align="center" rowspan="1" colspan="1">70 &#x000b1; 6.3</td><td align="center" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">98.6 &#x000b1; 6.2</td><td align="center" rowspan="1" colspan="1">100.8 &#x000b1; 12.6</td><td align="center" rowspan="1" colspan="1">0.2</td><td align="center" rowspan="1" colspan="1">98.8 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">96.3 &#x000b1; 6.9</td><td align="center" rowspan="1" colspan="1">0.17</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Biomarkers evaluation through the study (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Glucose <break/>(mg/dL)</th><th align="center" rowspan="1" colspan="1">HDL-C <break/>(mg/dL)</th><th align="center" rowspan="1" colspan="1">Triglycerides <break/>(mg/dL)</th><th align="center" rowspan="1" colspan="1">B-ALP <break/>(<italic>&#x000b5;</italic>g/mL)</th><th align="center" rowspan="1" colspan="1">Adiponectin <break/>(<italic>&#x000b5;</italic>g/mL)</th><th align="center" rowspan="1" colspan="1">Visfatin <break/>(ng/mL)</th><th align="center" rowspan="1" colspan="1">Resistin <break/>(<italic>&#x000b5;</italic>g/L)</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">NRT<break/>
</td><td align="center" rowspan="1" colspan="1">Basal</td><td align="center" rowspan="1" colspan="1">110 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">44 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">177 &#x000b1; 19</td><td align="center" rowspan="1" colspan="1">15 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">3.8 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 10</td></tr><tr><td align="center" rowspan="1" colspan="1"> 6 months</td><td align="center" rowspan="1" colspan="1">96 &#x000b1; 7*</td><td align="center" rowspan="1" colspan="1">50 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">145 &#x000b1; 14*</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 7**</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">2.8 &#x000b1; 0.8***</td><td align="center" rowspan="1" colspan="1">27 &#x000b1; 7**</td></tr><tr><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">98 &#x000b1; 6<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">50 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">156 &#x000b1; 15<sup>&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 6<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 5<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">2.9 &#x000b1; 1<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 8<sup>&#x000a7;&#x000a7;</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Basal versus 6 months</td><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">0.0016</td></tr><tr><td align="center" colspan="9" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">Basal</td><td align="center" rowspan="1" colspan="1">105 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">45 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">180 &#x000b1; 20</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">22 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">4 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">30 &#x000b1; 9</td></tr><tr><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">108 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">46 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">165 &#x000b1; 18</td><td align="center" rowspan="1" colspan="1">15 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">3.7 &#x000b1; 1.1</td><td align="center" rowspan="1" colspan="1">32 &#x000b1; 8</td></tr><tr><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">110 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">48 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">176 &#x000b1; 22</td><td align="center" rowspan="1" colspan="1">12 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">12 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">4 &#x000b1; 0.6</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 10</td></tr><tr><td align="left" rowspan="1" colspan="1">Basal versus 6 months</td><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">0.0013</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">0.42</td></tr></tbody></table><table-wrap-foot><fn><p>*<italic>P</italic> &#x0003c; 0.001 versus placebo 6 months; <italic>P</italic> = 0.004 versus placebo 6 and 12 months;
**<italic>P</italic> = 0.02 versus placebo 6 months;
***<italic>P</italic> = 0.001 versus placebo 6 months; <sup>##</sup>
<italic>P</italic> &#x0003c; 0.001 versus placebo 12 months; <sup>&#x000a7;</sup>
<italic>P</italic> = 0.004 versus placebo 12 months; <sup>&#x000a7;&#x000a7;</sup>
<italic>P</italic> = 0.009 versus placebo 12 months.</p></fn></table-wrap-foot></table-wrap></floats-group></article>